Table 2.

Estimated OR and 95%CI of pairwise meta-analysis for non-hematologic toxicity events in advanced or metastatic pancreatic cancer patients.

		Toxicity events		Pairwise meta-analysis
Included studies	Comparisons	Treatment1	Treatment2	OR (95%CI)
Non-hematologic (all grades)
Rash
1 study	A vs. B	43/308	43/305	0.99 (0.63–1.56)
1 study	A vs. C	20/80	38/80	0.37 (0.19–0.72)
1 study	A vs. F	29/280	72/282	0.34 (0.21–0.54)
1 study	A vs. G	15/342	18/331	0.80 (0.40–1.61)
Diarrhea
1 study	A vs. B	68/308	101/305	0.57 (0.40–0.82)
1 study	A vs. C	22/80	43/80	0.33 (0.17–0.63)
1 study	A vs. D	29/52	49/50	0.03 (0.00–0.20)
1 study	A vs. F	41/280	56/282	0.69 (0.44–1.08)
1 study	A vs. G	25/342	37/331	0.63 (0.37–1.07)
Stomatitis
1 study	A vs. B	12/308	52/305	0.20 (0.10–0.38)
1 study	A vs. C	22/80	43/80	0.17 (0.07–0.37)
1 study	A vs. D	29/52	49/50	0.06 (0.02–0.18)
1 study	A vs. F	41/280	56/282	0.59 (0.30–1.18)
Non-hematologic (grade≥3)
Rash
1 study	A vs. B	3/308	3/305	0.99 (0.20–4.94)
1 study	A vs. C	0/80	5/80	0.09 (0.00–1.57)
1 study	A vs. F	1/280	6/282	0.16 (0.02–1.38)
1 study	A vs. G	1/342	2/331	0.48 (0.04–5.35)
Diarrhea
1 study	A vs. B	6/308	3/305	2.00 (0.50–8.07)
1 study	A vs. C	1/80	6/80	0.16 (0.02–1.33)
1 study	A vs. D	6/52	4/50	1.50 (0.40–5.67)
1 study	A vs. F	2/280	6/282	0.33 (0.07–1.65)
1 study	A vs. G	3/342	4/331	0.72 (0.16–3.26)
Stomatitis
1 study	A vs. B	1/308	1/305	0.99 (0.06–15.90)
1 study	A vs. C	0/80	2/80	0.20 (0.01–4.13)
1 study	A vs. D	0/52	4/50	0.10 (0.01–1.88)
1 study	A vs. F	1/280	1/282	1.01 (0.06–1.18)

Notes: OR = odds ratio; 95%CI = 95% confidence intervals; A = Gemcitabine+Placebo; B = Gemcitabine+Axitinib; C = Gemcitabine+Trametinib; D = Gemcitabine+Sorafenib; F = Gemcitabine+Erlotinib; G = Gemcitabine+Tipifarnib.